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Up to one third of the population will die as a direct result of cancer. Accurate and timely diagnosis of disease often requires
multiple diﬀerent approaches including the use of modern imaging techniques. Prompt recognition of adverse consequences of
some anti-cancer therapies also requires a knowledge of the optimum imaging strategy for the problem at hand. The purpose
of this article is to review not only some of the commoner cardiovascular manifestations of malignancy but also to discuss the
strengths, weaknesses and appropriate use of cardiovascular imaging modalities.
1.Introduction
The heart is sometimes overlooked when considering the
myriad systemic eﬀects of cancer. However, cardiovascu-
lar manifestations of malignant disease (or its treatment)
are not rare, are often signiﬁcant, and have historically
been diagnosed late in the natural history of disease—
or even remained undetected until postmortem. In the
past, clinicians relied upon echocardiography to conﬁrm
cardiac involvement in malignant disease. However, con-
temporaneous noninvasive cardiac imaging with computed
tomography (CT) and cardiovascular magnetic resonance
(CMR) oﬀers unparalleled opportunities for early diagnosis
and surveillance in this patient population.
This paper will focus on the speciﬁc (and often com-
plementary) roles of the four principal noninvasive imag-
ing modalities (echocardiography, multidetector computed
tomography (MDCT), cardiac magnetic resonance (CMR),
and nuclear medicine) in patients with cancer[1, 2].Because
there is considerable overlap between the techniques in
regard to their clinical indications, our goal is to familiarize
the clinician with the strengths and limitations of each
modality to facilitate rational investigation for each speciﬁc
clinical scenario.
2.Noninvasive Imaging Modalitiesfor
EvaluationofCardiacMassesand Malignant
CardiovascularDisease
2.1. Echocardiography. Echocardiography remains the pri-
mary mode of initial investigation in suspected cardiovascu-
lar involvement by malignant disease [3]. This is by virtue
not only of its availability, portability, and low cost but
also because of its uniquely high temporal resolution, which
oﬀers a “real-time” assessment of cardiac structures that
is currently unmatchable by CT or CMR at a comparable
spatial resolution [4]. Fast-moving structures like the mitral
or aortic valves can be accurately displayed over time [5].
Therefore, valvular involvement by disease, both malignant
and infective (as a possible consequence of neutropenia),
requires a very high temporal resolution in anemic, septic,2 Cardiology Research and Practice
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Figure 1: Left atrial myxoma. A lobulated mass is situated in the left atrium adjacent to the interatrial septum (a). On T2-weighted images,
the mass appears uniformly high signal ((b), white arrow). Note that the mass is less well appreciated on bright blood cine imaging ((c),
black arrow) and could be overlooked if it were smaller. Late gadolinium enhancement images (d) demonstrate patchy uptake of contrast
within the mass (black arrow). The location and imaging characteristics are fairly typical for myxoma.
and tachycardic patients. Transesophageal echo (TEE) oﬀers
the advantage of a rapid and very high resolution survey of
the valves and cardiac chambers in patients who may be too
sick to undergo any other form of imaging [6].
A further advantage of echocardiography is its relative
robustness in the face of sustained arrhythmia or frequent
premature atrial or ventricular contractions. Image quality
can be maintained in the face of signiﬁcant rhythm dis-
turbance unlike CT and CMR which usually “construct”
an image based on an average of data derived from
multiple sequential heart beats using a process known
as “segmentation.” Thus the varying cardiac cycle lengths
introduced by arrhythmia cause considerable image per-
turbation frequently rendering the study nondiagnostic.
Echocardiography is not subject to these constraints since
multiple frames are acquired real-time in a single cardiac
cycle, avoiding the need for segmentation [7].
Newer techniques in echocardiography have been less
well studied in malignancy. Interrogation of myocardial
strain using tissue Doppler or speckle tracking may pro-
vide earlier warning of chemotherapy-induced dysfunction
than standard 2D echo techniques [8]. Three-dimensional
echocardiography is in its infancy, and its clinical utility in
thediagnosticevaluationofmalignancy hasnotyetbeenwell
characterized [9].
2.2. Multidetector Computed Tomography (MDCT). CT is
a versatile technique that has evolved rapidly in the last
decade. Multidetector computed tomography (MDCT) was
revolutionized by the invention of the 4 slice scanner in 2001
and has progressed through iterations that have involved
16, 32, 64, 256, and currently 320 detector rows. This has
reduced the time required to scan an entire thorax from
40 seconds to a minimum of only 1 or 2 seconds. This
is especially valuable for sick, intubated, or claustrophobic
patients. The utility of MDCT has been further increased
with the development of software for the scanner that
permits cardiac gating.Images may beacquiredata relatively
quiescent point towards end diastole, eﬀectively “freezing”
all cardiac motion. This, combined with the exquisite spatial
resolution of MDCT, oﬀers major advantages for assessment
of the cardiac chambers, pericardium and surrounding
vascular structures [10].
NotonlydoescardiacMDCThavehighspatialresolution
(0.5–0.65mm in most cases) but this resolution is isotropic,
that is, the lengths of the imaging element—the voxel—
are equal in x, y,a n dz axes. This permits reconstruction
of the raw data set (acquired in the axial plane) along
any axis desired without any discernible loss of image
quality. Interrogation of an abnormality in any plane desired
makes MDCT an extremely powerful tool. This reformattingCardiology Research and Practice 3
Table 1: Relative strengths and weaknesses of non-invasive imaging modalities.
ECHO MDCT CMR RNA
Availability ++++ +++ + ++
Temporal resolution ++++ ++ +++ +
Spatial resolution ++ ++++ +++ +
Contrast resolution ++ +++ ++++ +
Cost Low Medium High Low
Thoracic vessels + ++++ ++++ −
Cardiac function +++ ++ ++++ +++
Speed of acquisition +++ ++++ + ++
Radiation None Moderate None Moderate
Tissue characterization + ++ +++ −
Suitability for sick or claustrophobic patients ++++ ++++ +/− +/−
∗
(a)
∗
(b)
∗
(c)
∗
(d)
∗
(e)
∗
(f)
Figure 2: Fibroma. An ovoid mass partially obstructs the right ventricular outﬂow tract ((a)–(f), asterisk). The mass is of intermediate
intensity on T1-weighted imaging ((a) and (b)) and low signal on T2-weighted imaging (c). This combination of ﬁndings would make
malignancyrelatively unlikelysincemanyneoplasmshavea relatively highwater content andthusare high signalonT2 sequences. Dramatic
contrast uptake is, however, evident on the postgadolinium images ((e) and (f)). Dense ﬁbrous tumors may behave in this way, and the
diagnosis of ﬁbroma was later conﬁrmed.
occurs after the patient has left, which allows ﬂexibility in
postprocessingworkﬂow.Thisisanimportantdistinguishing
feature from the common bright-blood gradient echo or
steady-state sequences used to evaluate cardiac anatomy
and function in CMR, which are not isotropic and require
accurate planning of cardiac planes prospectively.
Noncontrast MDCT is of limited value for soft tissue
assessment other than lung parenchyma. It is, however,
very sensitive for calcium and is the technique of choice to
conﬁrm pericardial calciﬁcation in the context of possible
constriction. For assessment of the cardiac chambers and
thoracic vasculature, administration of iodinated contrast4 Cardiology Research and Practice
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Figure 3: Teratoma. A well-circumscribed solid mass is present adjacent to the right atrial appendage ((b), (c), (f) asterisk). Foci of low
attenuation are identiﬁed within it on noncontrast axial MDCT ((a), white arrows). Similar areas can be seen on the T1-weighted image
((d), white arrow) and show signal “dropout” with a fat-suppressed sequence ((e), white arrow). The presence of fat in a mixed density
mediastinal lesion raised the possibility of teratoma, and this diagnosis was conﬁrmed at pathology.
medium is required. This poses a problem in patients with
chronic kidney disease, especially in the presence of diabetes.
This may in some cases constitute a contraindication to the
study because of the risk of contrast-induced nephropathy
(CIN). Patients with GFR lower than threshold (often
deﬁned as <30mL/min/kg) may receive contrast after careful
consideration of risk/beneﬁt ratio but the possibility of
worsening nephropathy and potential dialysis has to be
discussed [11, 12].
The principal disadvantage of MDCTis patient radiation
exposure.However,thisneedstobeconsideredinthecontext
of the patient’s pre-existing malignancy and the overall
likelihood of beneﬁt from the scan [13]. Thoracic MDCT
dosesvary widely accordingtothescan parameters used.The
mean eﬀective dose can be anywhere between 5 and 25mSv
for asingle examination (theminimum and maximum doses
quoted are roughly the same as for conventional coronary
angiography and technetium MIBI nuclear study, resp.).
Of particular concern is the radiation dose to the female
breasts, lungs, and esophagus/thymus because these organs
are sensitive to radiation-induced carcinogenesis [14].
2.3. Cardiovascular Magnetic Resonance (CMR). CMR is
generally underutilized in the assessment of cardiovascular
m a l i g n a n c y .T h i si sp r i m a r i l yb e cause of a lack of availability
and expertise in this ﬁeld outside of large centers.
CMR combines good spatial and acceptable (segmented)
temporal resolution with unsurpassed soft tissue contrast
resolution over a much wider dynamic range than MDCT.
Not only is it excellent for anatomical assessment, it also
provides hemodynamic information regarding ﬂow veloc-
ity, biventricular volume and systolic function, and tissue
characterization. The latter is a major strength; T2-weighted
sequences may demonstrate that a mass has a high water
content (raising suspicion of neoplasia in the appropriate
context) or may, for example, demonstrate pericardial
inﬂammation after radiotherapy as a cause for a patient’s
atypical chest pain. Administration of gadolinium-based
contrast agents (GBCAs) can be combined with imaging
sequences that are particularly sensitive to the uptake of
gadolinium. The rate of uptake and pattern of enhancement
may oﬀer further insights into the underlying pathology and
frequentlyenableadistinctionbetweentumorand thrombus
to be made with conﬁdence[15]. NonethelessCMR doesnot
allow precise histopathological diagnosis in the majority of
cases.
Measurement of LV volumes and function is highly
reproducible by CMR, much more so than for any other
modality [16]. Screening for small decrements in ventricularCardiology Research and Practice 5
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Figure 4: Bronchogeniccarcinoma.A large mass(asterisk)is showninaxial((a) and(b)) andcoronal((c) and (d)) planes. OnT1-weighted
images the mass demonstrates signiﬁcant near-uniform enhancement after gadolinium contrast ((a) and (c) before contrast; (b) and (d)
after contrast).The massinﬁltrates posterior to the carina ((a),white arrow) and occludes the left mainbronchus ((c) and(d), white arrow).
The left main pulmonary artery is severely attenuated ((c), black arrow).
Table 2: Chemotherapeutic agents associated with left ventricular
dysfunction.
Chemotherapy agents
Anthracyclines
Doxorubicin
Epirubicin
Idarubicin
Alkylating agents
Cyclophosphamide
Ifosfamide
Antimetabolites
Docetaxel
Monoclonalantibody-based tyrosine kinase inhibitors
Bevacizumab
Trastuzumab
Proteasome inhibitor
Bortezomib
Small molecule tyrosine kinaseinhibitors
Dasatinib
Imatinib mesylate
Lapatinib
Sunitinib
function in patients receiving cardiotoxic chemotherapy
is a function that has been historically performed by
radionuclide angiography. In the future it seems probable
that CMR will take on at least a portion of this work
perhapstargetingtheyoungerpatientswhohavemosttogain
from sequential followup with a technique that involves no
ionizing radiation.
Angiographic delineation of the major vascular struc-
tures in the chest is readily achieved by CMR using both
static “snapshot” imaging and time-resolved magnetic res-
onance angiography which delineates the passage of contrast
throughthevasculartreeprovidingdiﬀerentialenhancement
of arterial and venous structures. This may be useful in
establishing degree of obstruction in, for example, SVC
syndrome as well as facilitating interventional planning.
A certain amount of subjective information may also be
gained about relative lung perfusion in cases of unilateral
tumor involvement of the pulmonary arteries or veins,
with delayed parenchymal blush often occurring on the
obstructed side. Formal measurements of relative ﬂow may
be made using phase velocity mapping which is a ﬂow
sensitive technique akin to echo Doppler. The ability to
interrogate a vessel in any plane renders CMR far more
ﬂexible than its sister modality.
CMR has both limitations and deﬁnite exclusions.
Amongst the former, a numberlackavailabilityand expertise
both to perform and interpret the studies. CMR is also
rarely a rapid method of gathering data and so is poorly
tolerated by the claustrophobic and very unwell for whom
the challenge of remaining still and breath holding repeti-
tively on command is often insurmountable. Symptomatic
claustrophobia is very common occurring in up to 25% of
patients although only 5-6% of all patients fail to complete
an exam for this reason [17].6 Cardiology Research and Practice
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Figure 5: Epicardial fat. Echocardiography raised concerns about excessive soft tissue anterior to the right ventricle in this patient on
long-term steroids. Bright blood cine (a) and T1-weighted images (b) show circumferential high signal around the heart (asterisks). The
appearances suggest an unusual amount of pericardial fat, and this was conﬁrmed on fat-suppressed CMR (c) where there is evidence of
signal drop out from the fatty region (asterisks—compare with (b)). MDCT is also very sensitive for fat which it displays as low-density
regions of negative Hounsﬁeld attenuation ((d), asterisks). Excessive mediastinal lipomatosis is not uncommon in patients taking steroid
preparations.
Critically ill patients may be unable to enter the scan
room if attached to standard infusion pumps because of
possible magnetic interference. Similarly the presence of a
pacemaker or deﬁbrillator currently remains a near-absolute
contraindication to CMR in most institutions worldwide.
Pregnancy is not an absolute contraindication of itself;
attempts are generally made to keep the radiofrequency
p o w e rd e p o s i t i o nl e v e l sa sl o wa sp o s s i b l ep r i m a r i l yb e c a u s e
of theoretical concerns about heating of the fetus. Similarly
gadolinium contrast is generally not given although there are
nodatatosuggestharmtothefetusatstandardclinicaldoses.
In many of the situations where CMR is diﬃcult or
contraindicated, the patient may be equally well served by
a timely MDCT study plus echo where function or ﬂow data
is vital.
2.4. Nuclear Medicine: Radionuclide Angiography (RNA).
The main goal of RNA is the visualization of the cardiac
chambers and great vessels. This requires the temporary
labeling of the blood with a suitable radioactive tracer. It
providesanaccurateevaluationofthestructureand function
oftheheart,includingejectionfraction,regionalwallmotion
variability, and diastolic function [18].
RNA is widely used for the assessment of the cardiac
function after chemotherapy, principally because of its ready
availability[19].However,althoughitsreproducibilityisvery
high, themain disadvantages ofRNAare its limitedtemporal
resolution and the use of ionizing radiation (approx. 3–
6mSv), which makes CMR a more attractive and highly
reproducible method of evaluating cardiac function without
a radiation penalty [20].
Therelativemeritsanddemeritsofeachofthe4principal
modalities discussed above are summarized in Table 1.
3.Multi-ModalityImaging inSpeciﬁc
ClinicalScenarios
3.1. Characterisation of Cardiac Tumors. Cardiac tumors
may be categorised as either primary or secondary. Primary
tumors are rare, ranging from 0.001% to 0.030% [21]
and three quarters of these tumors are benign. The most
common primary tumor is myxoma (Figure 1) (about50%);
the remainder includes lipoma, papillary ﬁbroelastoma,
cavernous hemangioma, ﬁbroma (Figure 2), rhabdomyoma,
paraganglioma, mediastinal teratoma (Figure 3), and lym-
phangioma. Of the malignant primary tumours, about 95%
are sarcomas and 5% are primary lymphomas and primary
cardiac carcinoid.
Secondary tumors, however, are much more common
than primary tumors, with an incidence of metastasis to
heart of 10% [22, 23]. The most frequent underlying
malignant origin is the lung (Figure 4). Secondary involve-
ment may be the result of direct invasion, lymphatic orCardiology Research and Practice 7
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Figure 6: Mitral annular calciﬁcation (MAC). A classic “pseudotumour” MAC is seen in older patients, often with a history of diabetes or
hypertension. It presents as focal mass-like lesions most frequently adjacent to the lateral mitral annulus ((a) and (b), white arrow). In this
example the signalcharacteristics onCMR are typically being low signalonT1-weighted images (a)and T2-weighted images(b).Its relation
to the posterior mitral annulus is well appreciated on the short axis bright-blood cine view ((c), white arrow). Noncontrast MDCT excludes
any residual diagnosis about the diagnosis—themass is of very high attenuation consistent with calcium ((d), white arrow).
hematogenous spread. In rare cases, direct transvascular
extension may occur (e.g., renal cell carcinoma extending
into the right heart via the inferior vena cava). The detection
of a cardiac mass should therefore always lead to a screen for
primary malignancy elsewhere in the body.
There is a group of nonneoplastic conditions of the
heart and pericardium that can mimic cardiac tumors.
These include pericardial cysts, lymphadenopathy, lipo-
matous hypertrophy of the atrial septum, pericardial fat
(Figure 5), caseous calciﬁcation of mitral valve [24], coro-
nary artery aneurysm, and thrombus. Despite the lack of
malignant potential of these lesions, they can be associated
with considerable morbidity and even mortality due to
inappropriate treatment. For this reason, their recognition
and diﬀerentiation from malignant tumors is crucial [25].
The most frequent pseudotumor is thrombus, which is
discussed separately below.
Fordiagnosis of cardiac tumors, TTE and TEE are widely
used as they can localize the tumor and give informa-
tion about size, shape, attachment, and mobility. Contrast
echocardiography is also used for assessment of intracardiac
masses [26]. However, for complex tumors and large or
inﬁltrating tumors, the combination of echocardiography
with either MRI or MDCT provides better deﬁnition and
more precise preoperative planning [27].
T u m o rb r e a c ho ft i s s u ep l a n e si so f t e nd e p i c t e dw i t h
greater certainty by MDCT than CMR due to better spatial
resolution. Detection of small amounts of tumor may be
betterby CMR because of its superior contrast resolution for
soft tissue. The presence of calcium, however, is recognised
with greater ease using MDCT than CMR which can be
helpful when assessing mitral valve masses (Figure 6).
3.2. Thrombus. Thrombus is the most common intracardiac
mass involving the left ventricle or left atrium [28]. Its
identiﬁcation and proper characterization is very important
so that anticoagulant therapy is not delayed (Figure 7).
Although TTE can detect the presence of thrombus and is
usually the primary screening tool, it has limited sensitivity
for this purpose [29]. Laminated mural thrombi may be
diﬃcult to distinguish from myocardium and slow blood
ﬂow within aneurysms. Late gadolinium enhancement CMR
is very sensitive for the presence of thrombus [30]. Several
distinguishing CT imaging features have been described to
diﬀerentiate thrombus from other tumors including size,
origin, shape, and prolapse [31]. However, the accuracy of
MDCT in this regard has not been established in any large
studies.
3.3. Pericardial Disease. Pericardial disease related to cancer
encompasses both the direct eﬀects of tumor invasion as
well as the indirect consequences of thoracic surgery and/or
radiotherapy.
The initial evaluation for pericardial eﬀusion is usu-
ally by transthoracic echo. Echocardiography is useful in
evaluating the physiological changes in pericardial diseases
[32]. Malignant pericardial eﬀusion is not uncommon, and
TTE is generally the most sensitive method for detecting8 Cardiology Research and Practice
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Figure 7: Thrombus. A coronal maximum intensity projection image from a contrast MDCT study demonstrates multiple pulmonary
emboli ((a), white arrows). On the same study the possibility of a right atrial mass was raised ((b), white arrow), although it was uncertain
whether this was real or simply an appearance due to incomplete mixing of opaciﬁed SVC blood with unopaciﬁed IVC blood. Cine CMR
demonstratesthatthe massis clearlyreal ((c),black arrow).Further characterizationby CMR demonstrates thatthe massis lowsignalonT1
weighted images ((d), white arrow) and remains low signal following gadolinium administration ((e), white arrow). The appearances and
clinical presentation were entirely consistent with right atrial thrombus. The mass disappeared with subsequent anticoagulation.
both incipient and frank tamponade (Figure 8). However,
it is limited in the assessment of pericardial extension,
pericardial thickening,and inﬂammation, whereas CMRand
MDCT excel in this regard. MDCT is the best technique
for depiction of pericardial calciﬁcation. In addition, the
composition of pericardial collections (simple or complex)
may be inferred from measurements of Hounsﬁeld density.
This may guide subsequent management since complex
collections are unlikely to respond well to percutaneous
drainage and often require surgical intervention.
CMR is better at diﬀerentiating small pericardial eﬀu-
sions from pericardial thickening and provides a functional
and structural assessment of the pericardium. CMR can also
evaluate physiological consequences of pericardial constric-
tion. Speciﬁc imaging techniques for pericardial constric-
tion include cine-tagged imaging which can demonstrate
tethering of the myocardium during systole. Real-time cine
imaging may be used to demonstrate septal bounce seen in
constriction [33].
CMR may show pericardial inﬂammation (e.g., acutely
after radiotherapy) with T2-weighted or late gadolinium
enhancement imaging.
4.CardiovascularComplicationsof
CancerTherapy
The therapeutic options for patients with cancer include
complex combinations of medications, radiation therapy,
and surgery. Many of these treatments have important
potential adverse cardiovascular eﬀects. Indeed, cardiovas-
cular events represent the second most common cause of
mortality after cancer recurrence [34]. Although there is
no uniﬁed consensus for the assessment and monitoring
of the cardiovascular complications of cancer treatment,
noninvasive imaging is increasingly used [35].
4.1.Radiation. Mediastinal irradiation isnotuncommonfor
solid and lymphomatous malignancies involving the chest
[36]. The potential adverse eﬀects include arteritis, peri-
carditis, cardiomyopathy, valvular disease, and conduction
anomalies.
Radiation-induced valvular disease is limited, aﬀecting
approximately 6–15% of patients exposed to mediastinal
radiation [37]. Valvular regurgitation is more common [38].
The typicalﬁndings includevalvular thickening,ﬁbrosis,andCardiology Research and Practice 9
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Figure 8: Echo signs of tamponade. Diastolic inversion of the right atrial (RA) free wall is an early sign of raised intrapericardial pressure
((a) and (b)), white arrow—note collapse/inversion of the RA free wall in early diastole (b) as the intrapericardial pressure exceeds the RA
pressure. Right ventricular diastolicinversion is a later but more speciﬁc sign of tamponade((c) and(d)) asterisksoutlinethe RV free wall—
the RV showsdiastoliccollapse (d) due to the adjacent eﬀusion (PE). Note also the relative enlargement of the left ventricle (LV) in this case;
a result of chemotherapy-related cardiomyopathy. Doppler techniques are often very helpful in establishing the diagnosis of tamponade—
transtricuspid ﬂow variability ofgreater than33% ona beat-to-beat basis ((e),asterisks represent peak transtricuspid ﬂow for each recorded
beat) is suggestive of tamponade. M-mode Doppler has a very high sampling (frame) rate compared to standard B-mode Doppler and is
therefore useful for timing the motion of the RV free wall with respect to the cardiac cycle ((f), horizontal white arrows indicate the RV free
wall; as would be expected this moves in normallyduring systole but is slow to move outwards in early-to-mid diastole (black asterisks)—in
fact full outward excursion only occurs late in diastole (dotted short arrow) aided by the ﬁlling from atrial contraction (dotted long arrow
indicates P wave on ECG, i.e., atrial systole)).
calciﬁcations. TEE is the best imaging modality to evaluate
valvular function.
Pericardial disease induced by radiation is typically
a long-term complication and may develop years after
treatment, manifesting as silent pericardial eﬀusions or with
constrictive pericarditis, with or without pericardial ﬂuid.
Echo together with CMR may both be required to support
a clinical diagnosis of constriction. Cardiomyopathy after
radiation is predominantly due to diastolic dysfunction with
a restrictive pattern—these features may be most evident
on echo which is best suited to evaluate abnormalities of
diastolic function. This is primarily because of its very high
temporal resolution which permits beat-to-beat (real-time)
measurement of the transmitral ﬂow abnormalities which
characterize diastolic impairment.
4.2. Chemotherapy. Many chemotherapy drugs have the
potential to cause cardiotoxicity. The chemotherapy agents
associated with LV dysfunction are shown in Table 2.
Diﬀerent expert working groups have developed practice
guidelines for cardiac monitoring requirements in patients10 Cardiology Research and Practice
undergoing chemotherapy. For example, the recommenda-
tions of the Canadian Trastuzumab working group include
LVEF assessment before trastuzumab treatment is started
and repeated every 3 months until completion of therapy.
Several authors have also described development of myocar-
dial ﬁbrosis in conjunction with certain chemotherapeutic
agents demonstrated by late gadolinium enhancement on
CMR [39].
4.3. Others. The use of devices for chemotherapy, such
as indwelling venous catheters, predisposes to thrombus
formationtypicallyatthetipofthecatheter.Thisisoftenwell
depicted by CMR. MDCT can be confusing since incomplete
mixing in the right atrium during the ﬁrst pass of contrast
often simulatesﬁlling defects—deﬁniteCT conﬁrmation ofa
realmassisbestachievedbyperformingadelayedacquisition
1-2 minutes after contrast injection.
5.Conclusion
The extentof potential cardiovascular involvementby malig-
nancy is broad. Four main non-invasive imaging methods
are available for evaluation of suspected cardiovascular com-
plications of malignancy. They are useful for the exclusion
of other diseases and to guide proper management of these
patients. Non-invasive imagers are well educated in the
strengths and weaknesses of the various imaging techniques;
optimum use of this expensive technology is most eﬃcient
when proper dialogue occurs between cancer and imaging
specialists.
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